62nd ASH Annual Meeting and Exposition: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells

Oral and Poster Abstracts
Oral

AML, Biological, Coronaviruses, SARS-CoV-2/COVID-19, viral, bone marrow, Diseases, iPSCs, CAR-Ts, Therapies, Biological Processes, immune cells, Technology and Procedures, Cell Lineage, immunotherapy, Infectious Diseases, gene editing, infusion, Clinically relevant, Myeloid Malignancies, NK cells, transfusion, transplantation, stem cells

Moderators:

Mark Eric Kohler, MD, PhD, Children's Hospital Colorado - University of Colorado Anschutz and Eric L Smith, MD, PhD, Memorial Sloan Kettering Cancer Center

Disclosures:

Smith: Bristol Myers Squibb: Consultancy, Patents & Royalties, Research Funding; Fate Therapeutics: Consultancy; Precision Biosciences: Consultancy.

9:00 AM

608

Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial

Tang Baolin^1,2^*, Jongbok Lee, BSc³^*, Siqi Cheng¹^*, Wen Yao¹^*, Dongyao Wang, PhD¹, Meijuan Tu¹^*, Zhiqiang Xiang⁴^*, Liangquan Geng¹^*, Mingxia Wang⁴^*, Ping Qiang, MD¹^*, Pingping Teng⁴^*, Guangyu Sun¹^*, Tianzhong Pan¹^*, Huilan Liu^1,2^*, Liming Yang⁴^*, Zimin Sun^1,2^*, Li Zhang, MD, PhD³^* and Xiaoyu Zhu, Doctor^2,5^*

¹Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
²Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
⁴Ruichuang Biotechnology Co., Hangzhou, China
⁵Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China

9:15 AM

609

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Ifigeneia Tzannou, MD¹^*, Ayumi Watanabe, Bsc²^*, Anastasia Papadopoulou, PhD^1,3^*, Manik Kuvalekar, Msc¹^*, Swati Naik, MBBS⁴, Premal Lulla, MBBS¹, Robert A. Krance, MD⁵, Carlos A. Ramos, MD¹, Helen E. Heslop, MD, DSc¹, Ann M. Leen, PhD⁶ and Bilal Omer, MD¹

¹Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
²Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
³Hematology Department & HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece
⁴Texas Children's Hospital, Baylor College of Medicine, Houston, TX
⁵Department of Pediatrics, Baylor College of Medicine Texas Children's Hospital, Houston, TX
⁶Pediatrics, Center for Cell & Gene Therapy, Houston, TX

9:30 AM

610

CRISPR Gene-Editing of Chemokine Receptors As a Novel Strategy to Redirect NK Cell Trafficking In Vivo

Emily R. Levy, PhD^*, Joseph Clara, MD, David Allan, PhD^*, Robert Reger, MS^* and Richard W. Childs, MD^*

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

9:45 AM

611

Engineered Memory-like NK Cars Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia

Han Dong, PhD¹, Guozhu Xie, MD, PhD²^*, Yong Liang, MD, PhD¹^*, James Dongjoo Ham³^*, Juliana Vergara⁴^*, Jianzhu Chen, PhD²^*, Jerome Ritz, MD⁵ and Rizwan Romee, MD⁶

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Koch Institute, MIT, Cambridge, MA
³Massachusetts Institute of Technology, Cambridge, MA
⁴Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School, Boston, MA

10:00 AM

612

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Spyridoula Vasileiou, PhD¹^*, Manik Kuvalekar, Msc¹^*, Aster Workineh, Msc²^*, Ayumi Watanabe, Bsc¹^*, Yovana Velazquez, Bsc¹^*, Suhasini Lulla, Bsc¹^*, Helen E. Heslop, MD, DSc¹, Kimberly Mooney, Bsc¹^*, Kevin Grimes, MD³^*, George Carrum, MD¹, LaQuisa C. Hill, MD¹, Premal Lulla, MBBS¹ and Ann M. Leen, PhD¹

¹Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
²AlloVir, Houston, TX
³Houston Methodist Hospital, Houston, TX

10:15 AM

613

Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy

Ryan Bjordahl, PhD¹^*, John Goulding, PhD¹^*, Mochtar Pribadi, PhD¹^*, Robert Blum, MS¹^*, Chiawei Chang¹^*, Yijia Pan, PhD¹^*, Lucas Ferrari de Andrade, PhD²^*, Kai W. Wucherpfennig²^*, Yu-Waye Chu, MD³, Hui-yi Chu, PhD¹^*, Wen-I Yeh, PhD¹^*, Svetlana Gaidarova, MS¹^*, Ellen Liu, PhD¹^*, Shohreh Sikaroodi, PhD¹^*, Lauren Fong, PhD¹^*, Janel Huffman, MS¹^*, Tom Lee, PhD³^* and Bahram Valamehr, PhD³

¹Fate Therapeutics Inc., San Diego, CA
²Dana-Farber Cancer Institute, Boston, MA
³Fate Therapeutics, Inc., San Diego, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O2.6 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells